Key Takeaways Rigel's Tavalisse posted $68.5M in H1 2025 sales, which increased 44$13.1M, with Gavreto adding incremental revenues in 1H 2025.R289 phase Ib study in MDS moves to dose expansion, with dose escalation data expected later in 2025.Rigel Pharmaceuticals (RIGL) is making continued advancement related to the development of its hematology and oncology pipeline and products. The company’s first product, Tavalisse (fostamatinib disodium hexahydrate), has be ...